Prion disease: Chemotherapeutic strategies

Infectious Disorders - Drug Targets

Volumn 12, Issue 2, 2012, Pages 144-160

  Sim, Valerie L ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Chemotherapeutic; Conversion; Decontamination; Polyanion; Prion; Prophylaxis; PrP

Indexed keywords

ANTIBIOTIC AGENT; ANTIMONIOTUNGSTATE; ANTIVIRUS AGENT; APTAMER; CHELATING AGENT; CONGO RED; CURCUMIN; CYCLODEXTRIN; DEXTRAN SULFATE; DOXORUBICIN; DOXYCYCLINE; FUCOIDIN; GLATIRAMER; HEPARAN SULFATE; HYPOCHOLESTEROLEMIC AGENT; INDOLE DERIVATIVE; MEPACRINE; NEUROPROTECTIVE AGENT; OLIGONUCLEOTIDE PHOSPHOROTHIOATE; PENTOSAN POLYSULFATE; PEPTIDE DERIVATIVE; POLYANION; POLYSACCHARIDE; PRION PROTEIN; SURAMIN; TETRACYCLINE; TETRAPYRROLE DERIVATIVE; THIAZOLE DERIVATIVE; TRIMIPRAMINE; UNINDEXED DRUG;

AMINO TERMINAL SEQUENCE; AUTOPHAGY; BOVINE SPONGIFORM ENCEPHALOPATHY; CHEMOTHERAPY; CHRONIC WASTING DISEASE; DIAGNOSTIC TEST; DRUG PROTEIN BINDING; DRUG TARGETING; ENDOPLASMIC RETICULUM STRESS; HUMAN; NONHUMAN; PRION DISEASE; QUAKING INDUCED CONVERSION ASSAY; REVIEW; SCREENING TEST; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; VARIANT CREUTZFELDT JAKOB DISEASE;

EID: 84860307590     PISSN: 18715265     EISSN: 18755852     Source Type: Journal    
DOI: 10.2174/187152612800100161     Document Type: Review

References (239)

1. Castilla, J.; Saa, P.; Hetz, C.; Soto, C. In vitro generation of infectious scrapie prions. Cell, 2005, 121(2), 195-206.
2. Deleault, N.R.; Harris, B.T.; Rees, J.R.; Supattapone, S. Formation of native prions from minimal components in vitro. Proc. Natl. Acad. Sci. USA, 2007, 104(23), 9741-9746.
3. Baron, D.; Assaraf, Y.G.; Cohen, N.; Aronheim, A. Lack of plasma membrane targeting of a G172D mutant thiamine transporter derived from Rogers syndrome family. Mol. Med., 2002, 8(8), 462-474.
4. Caughey, B.; Raymond, G.J. The scrapie-associated form of PrP is made from a cell surface precursor that is both protease-and phospholipase-sensitive. J. Biol. Chem., 1991, 266(27), 18217-18223.
5. Caughey, B.; Raymond, G.J.; Ernst, D.; Race, R.E. N-terminal truncation of the scrapie-associated form of PrP by lysosomal protease(s): implications regarding the site of conversion of PrP to the protease-resistant state. J. Virol., 1991, 65(12), 6597-6603.
6. Borchelt, D.R.; Taraboulos, A.; Prusiner, S.B. Evidence for synthesis of scrapie prion proteins in the endocytic pathway. J. Biol. Chem., 1992, 267(23), 16188-16199.
7. Chesebro, B.; Trifilo, M.; Race, R.; Meade-White, K.; Teng, C.; LaCasse, R.; Raymond, L.; Favara, C.; Baron, G.; Priola, S.; Caughey, B.; Masliah, E.; Oldstone, M. Anchorless prion protein results in infectious amyloid disease without clinical scrapie. Science, 2005, 308(5727), 1435-1439.
8. Berardi, V.A.; Cardone, F.; Valanzano, A.; Lu, M.; Pocchiari, M. Preparation of soluble infectious samples from scrapie-infected brain: a new tool to study the clearance of transmissible spongiform encephalopathy agents during plasma fractionation. Transfusion, 2006, 46(4), 652-658.
9. Silveira, J.R.; Raymond, G.J.; Hughson, A.G.; Race, R.E.; Sim, V.L.; Hayes, S.F.; Caughey, B. The most infectious prion protein particles. Nature, 2005, 437(7056), 257-261.
10. Pastrana, M.A.; Sajnani, G.; Onisko, B.; Castilla, J.; Morales, R.; Soto, C.; Requena, J.R. Isolation and characterization of a proteinase K-sensitive PrPSc fraction. Biochemistry, 2006, 45(51), 15710-15717.
11. Tzaban, S.; Friedlander, G.; Schonberger, O.; Horonchik, L.; Yedidia, Y.; Shaked, G.; Gabizon, R.; Taraboulos, A. Proteasesensitive scrapie prion protein in aggregates of heterogeneous sizes. Biochemistry, 2002, 41(42), 12868-12875.
12. Novitskaya, V.; Bocharova, O.V.; Bronstein, I.; Baskakov, I.V. Amyloid fibrils of mammalian prion protein are highly toxic to cultured cells and primary neurons. J. Biol. Chem., 2006, 281(19), 13828-13836.
13. Kocisko, D.A.; Baron, G.S.; Rubenstein, R.; Chen, J.; Kuizon, S.; Caughey, B. New inhibitors of scrapie-associated prion protein formation in a library of 2000 drugs and natural products. J. Virol., 2003, 77(19), 10288-10294.
14. Kocisko, D.A.; Caughey, B. Searching for anti-prion compounds: cell-based high-throughput in vitro assays and animal testing strategies. Methods Enzymol., 2006, 412, 223-234.
15. Poncet-Montange, G.; St Martin, S.J.; Bogatova, O.V.; Prusiner, S.B.; Shoichet, B.K.; Ghaemmaghami, S. A survey of antiprion compounds reveals the prevalence of non-PrP molecular targets. J. Biol. Chem., 2011, 286(31), 27718-27728.
16. Geissen, M.; Leidel, F.; Eiden, M.; Hirschberger, T.; Fast, C.; Bertsch, U.; Tavan, P.; Giese, A.; Kretzschmar, H.; Schatzl, H.M.; Groschup, M.H. From high-throughput cell culture screening to mouse model: identification of new inhibitor classes against prion disease. ChemMedChem, 2011, 6(10), 1928-1937.
17. Bach, S.; Talarek, N.; Andrieu, T.; Vierfond, J.M.; Mettey, Y.; Galons, H.; Dormont, D.; Meijer, L.; Cullin, C.; Blondel, M. Isolation of drugs active against mammalian prions using a yeast-based screening assay 2. Nat. Biotechnol., 2003, 21(9), 1075-1081.
18. Kawatake, S.; Nishimura, Y.; Sakaguchi, S.; Iwaki, T.; Doh-ura, K. Surface plasmon resonance analysis for the screening of anti-prion compounds. Biol. Pharm. Bull., 2006, 29(5), 927-932.
19. Hosokawa-Muto, J.; Kamatari, Y.O.; Nakamura, H.K.; Kuwata, K. Variety of antiprion compounds discovered through an in silico screen based on cellular-form prion protein structure: Correlation between antiprion activity and binding affinity. Antimicrob. Agents Chemother., 2009, 53(2), 765-771.
20. Bertsch, U.; Winklhofer, K.F.; Hirschberger, T.; Bieschke, J.; Weber, P.; Hartl, F.U.; Tavan, P.; Tatzelt, J.; Kretzschmar, H.A.; Giese, A. Systematic identification of antiprion drugs by highthroughput screening based on scanning for intensely fluorescent targets 1. J. Virol., 2005, 79(12), 7785-7791.
21. Breydo, L.; Bocharova, O.V.; Baskakov, I.V. Semiautomated cellfree conversion of prion protein: applications for high-throughput screening of potential antiprion drugs 1. Anal. Biochem., 2005, 339(1), 165-173.
22. Kocisko, D.A.; Bertholet, N.; Moore, R.A.; Caughey, B.; Vaillant, A. Identification of prion inhibitors by a fluorescence-polarizationbased competitive binding assay. Anal. Biochem., 2007, 363(1), 154-156.
23. Perrier, V.; Wallace, A.C.; Kaneko, K.; Safar, J.; Prusiner, S.B.; Cohen, F.E. Mimicking dominant negative inhibition of prion replication through structure-based drug design. Proc. Natl. Acad. Sci. USA, 2000, 97(11), 6073-6078.
24. Reddy, T.R.; Mutter, R.; Heal, W.; Guo, K.; Gillet, V.J.; Pratt, S.; Chen, B. Library design, synthesis, and screening: pyridine dicarbonitriles as potential prion disease therapeutics. J. Med. Chem., 2006, 49(2), 607-615.
25. Atarashi, R.; Wilham, J.M.; Christensen, L.; Hughson, A.G.; Moore, R.A.; Johnson, L.M.; Onwubiko, H.A.; Priola, S.A.; Caughey, B. Simplified ultrasensitive prion detection by recombinant PrP conversion with shaking. Nat. Methods, 2008, 5(3), 211-212.
26. Wilham, J.M.; Orru, C.D.; Bessen, R.A.; Atarashi, R.; Sano, K.; Race, B.; Meade-White, K.D.; Taubner, L.M.; Timmes, A.; Caughey, B. Rapid end-point quantitation of prion seeding activity with sensitivity comparable to bioassays. PLoS Pathog., 2010, 6(12), e1001217.
27. Atarashi, R.; Sano, K.; Satoh, K.; Nishida, N. Real-time quakinginduced conversion: A highly sensitive assay for prion detection. Prion, 2011, 5(3), 150-153.
28. Atarashi, R.; Satoh, K.; Sano, K.; Fuse, T.; Yamaguchi, N.; Ishibashi, D.; Matsubara, T.; Nakagaki, T.; Yamanaka, H.; Shirabe, S.; Yamada, M.; Mizusawa, H.; Kitamoto, T.; Klug, G.; McGlade, A.; Collins, S.J.; Nishida, N. Ultrasensitive human prion detection in cerebrospinal fluid by real-time quaking-induced conversion. Nat. Med., 2011, 17(2), 175-178.
29. Orru, C.D.; Wilham, J.M.; Raymond, L.D.; Kuhn, F.; Schroeder, B.; Raeber, A.J.; Caughey, B. Prion disease blood test using immunoprecipitation and improved quaking-induced conversion. MBio, 2011, 2(3), e00078-11.
30. Brown, P.; Brandel, J.P.; Preece, M.; Sato, T. Iatrogenic Creutzfeldt-Jakob disease: the waning of an era. Neurology, 2006, 67(3), 389-393.
31. Hewitt, P.E.; Llewelyn, C.A.; Mackenzie, J.; Will, R.G. Creutzfeldt-Jakob disease and blood transfusion: results of the UK Transfusion Medicine Epidemiological Review study. Vox Sang., 2006, 91(3), 221-230.
32. Peden, A.; McCardle, L.; Head, M.W.; Love, S.; Ward, H.J.; Cousens, S.N.; Keeling, D.M.; Millar, C.M.; Hill, F.G.; Ironside, J.W. Variant CJD infection in the spleen of a neurologically asymptomatic UK adult patient with haemophilia. Haemophilia, 2010, 16(2), 296-304.
33. Caughey, B.; Caughey, W.S.; Kocisko, D.A.; Lee, K.S.; Silveira, J.R.; Morrey, J.D. Prions and transmissible spongiform encephalopathy (TSE) chemotherapeutics: a common mechanism for anti-TSE compounds? Accts. Chem. Res., 2006, 39, 646-653.
34. Caughey, W.S.; Priola, S.A.; Kocisko, D.A.; Raymond, L.D.; Ward, A.; Caughey, B. Cyclic tetrapyrrole sulfonation, metals, and oligomerization in antiprion activity. Antimicrob. Agents Chemother., 2007, 51(11), 3887-3894.
35. Scdependent cell-free formation of proteaseresistant prion protein. EMBO J., 2001, 20, 377-386.
36. Deleault, N.R.; Lucassen, R.W.; Supattapone, S. RNA molecules stimulate prion protein conversion. Nature, 2003, 425(6959), 717-720.
37. Caughey, B.; Kocisko, D.A. Prion diseases: a nucleic-acid accomplice? Nature, 2003, 425(6959), 673-674.
38. Shyng, S.L.; Lehmann, S.; Moulder, K.L.; Harris, D.A. Sulfated glycans stimulate endocytosis of the cellular isoform of the prion protein, PrPC, in cultured cells. J. Biol. Chem., 1995, 270(50), 30221-30229.
39. Caughey, B.; Raymond, G.J. Sulfated polyanion inhibition of scrapie-associated PrP accumulation in cultured cells. J. Virol., 1993, 67(2), 643-650.
40. Gabizon, R.; Meiner, Z.; Halimi, M.; Bensasson, S.A. Heparin-like molecules bind differentially to prion proteins and change their intracellular metabolic-fate. J. Cell. Physiol., 1993, 157, 319-325.
41. Caughey, B.; Brown, K.; Raymond, G.J.; Katzenstein, G.E.; Thresher, W. Binding of the protease-sensitive form of PrP (prion protein) to sulfated glycosaminoglycan and congo red. J. Virol., 1994, 68(4), 2135-2141.
42. Ben-Zaken, O.; Tzaban, S.; Tal, Y.; Horonchik, L.; Esko, J.D.; Vlodavsky, I.; Taraboulos, A. Cellular heparan sulfate participates in the metabolism of prions. J. Biol. Chem., 2003, 278(41), 40041-40049.
43. Karpuj, M.V.; Gelibter-Niv, S.; Tiran, A.; Rambold, A.; Tatzelt, J.; Nunziante, M.; Schatzl, H.M. Conditional modulation of membrane protein expression in cultured cells mediated by prion protein recognition of short phosphorothioate oligodeoxynucleotides. J. Biol. Chem., 2011, 286(9), 6911-6917.
44. Doh-ura, K.; Ishikawa, K.; Murakami-Kubo, I.; Sasaki, K.; Mohri, S.; Race, R.; Iwaki, T. Treatment of Transmissible Spongiform Encephalopathy by Intraventricular Drug Infusion in Animal Models. J. Virol., 2004, 78(10), 4999-5006.
45. Ehlers, B.; Diringer, H. Dextran sulphate 500 delays and prevents mouse scrapie by impairment of agent replication in spleen. J. Gen. Virol., 1984, 65, 1325-1330.
46. Diringer, H.; Ehlers, B. Chemoprophylaxis of scrapie in mice. J. Gen. Virol., 1991, 72, 457-460.
47. Farquhar, C.; Dickinson, A.; Bruce, M. Prophylactic potential of pentosan polysulphate in transmissible spongiform encephalopathies. Lancet, 1999, 353(9147), 117.
48. Ladogana, A.; Casaccia, P.; Ingrosso, L.; Cibati, M.; Salvatore, M.; Xi, Y.G.; Masullo, C.; Pocchiari, M. Sulphate polyanions prolong the incubation period of scrapie-infected hamsters. J. Gen. Virol., 1992, 73, 661-665.
49. Raymond, G.J.; Olsen, E.A.; Lee, K.S.; Raymond, L.D.; Bryant, P.K., III; Baron, G.S.; Caughey, W.S.; Kocisko, D.A.; McHolland, L.E.; Favara, C.; Langeveld, J.P.; van Zijderveld, F.G.; Mayer, R.T.; Miller, M.W.; Williams, E.S.; Caughey, B. Inhibition of protease-resistant prion protein formation in a transformed deer cell line infected with chronic wasting disease. J. Virol., 2006, 80(2), 596-604.
50. Larramendy-Gozalo, C.; Barret, A.; Daudigeos, E.; Mathieu, E.; Antonangeli, L.; Riffet, C.; Petit, E.; Papy-Garcia, D.; Barritault, D.; Brown, P.; Deslys, J.P. Comparison of CR36, a new heparan mimetic, and pentosan polysulfate in the treatment of prion diseases. J. Gen. Virol., 2007, 88, 1062-1067.
51. Todd, N.V.; Morrow, J.; Doh-ura, K.; Dealler, S.; O'Hare, S.; Farling, P.; Duddy, M.; Rainov, N.G. Cerebroventricular infusion of pentosan polysulphate in human variant Creutzfeldt-Jakob disease. J. Infect., 2005, 50(5), 394-396.
52. Rainov, N.G.; Tsuboi, Y.; Krolak-Salmon, P.; Vighetto, A.; Doh-Ura, K. Experimental treatments for human transmissible spongiform encephalopathies: is there a role for pentosan polysulfate? Expert Opin. Biol. Ther., 2007, 7(5), 713-726.
53. Bone, I.; Belton, L.; Walker, A.S.; Darbyshire, J. Intraventricular pentosan polysulphate in human prion diseases: an observational study in the UK. Eur. J. Neurol., 2008, 15(5), 458-464.
54. Tsuboi, Y.; Doh-Ura, K.; Yamada, T. Continuous intraventricular infusion of pentosan polysulfate: clinical trial against prion diseases. Neuropathology, 2009, 29(5), 632-636.
55. Honda, H.; Sasaki, K.; Minaki, H.; Masui, K.; Suzuki, S.O.; Doh-Ura, K.; Iwaki, T. Protease-resistant PrP and PrP oligomers in the brain in human prion diseases after intraventricular pentosan polysulfate infusion. Neuropathology, 2011, doi: 10.1111/j.1440-1789.2011.01245.x.
56. Prior, M.; Lehmann, S.; Sy, M.S.; Molloy, B.; McMahon, H.E. Cyclodextrins inhibit replication of scrapie prion protein in cell culture. J. Virol., 2007, 81(20), 11195-11207.
57. McEvoy, K.; McMahon, H.E. Antiprion action of new cyclodextrin analogues. Biochim. Biophys. Acta, 2009, 1790(10), 1382-1386.
58. Kocisko, D.A.; Vaillant, A.; Lee, K.S.; Arnold, K.M.; Bertholet, N.; Race, R.E.; Olsen, E.A.; Juteau, J.M.; Caughey, B. Potent antiscrapie activities of degenerate phosphorothioate oligonucleotides. Antimicrob. Agents Chemother., 2006, 50(3), 1034-1044.
59. Wang, F.; Wang, X.; Yuan, C.G.; Ma, J. Generating a prion with bacterially expressed recombinant prion protein. Science, 2010, 327(5969), 1132-1135.
60. Wang, F.; Zhang, Z.; Wang, X.; Li, J.; Zha, L.; Yuan, C.G.; Weissmann, C.; Ma, J. Genetic informational RNA is not required for recombinant prion infectivity. J. Virol., 2012, 86(3), 1874-1876.
61. Jeong, B.H.; Kim, N.H.; Jin, J.K.; Choi, J.K.; Lee, Y.J.; Kim, J.I.; Choi, E.K.; Carp, R.I.; Kim, Y.S. Reduction of prion infectivity and levels of scrapie prion protein by lithium aluminum hydride: implications for RNA in prion diseases. J. Neuropathol. Exp. Neurol., 2009, 68(8), 870-879.
62. Caughey, B.; Race, R.E. Potent inhibition of scrapie-associated PrP accumulation by Congo red. J. Neurochem., 1992, 59, 768-771.
63. Woody, A.M.; Reisbig, R.R.; Woody, R.W. Spectroscopic studies of Congo red binding to RNA polymerase. Biochim. Biophys. Acta, 1981, 655, 82-88.
64. Priola, S.A.; Caughey, B. Inhibition of scrapie-associated PrP accumulation: Probing the role of glycosaminoglycans in amyloidogenesis. Mol. Neurobiol., 1994, 8, 113-120.
65. Caspi, S.; Halimi, M.; Yanai, A.; Sasson, S.B.; Taraboulos, A.; Gabizon, R. The anti-prion activity of Congo red. Putative mechanism. J. Biol. Chem., 1998, 273(6), 3484-3489.
66. Caughey, B.; Ernst, D.; Race, R.E. Congo red inhibition of scrapie agent replication. J. Virol., 1993, 67, 6270-6272.
67. Demaimay, R.; Harper, J.; Gordon, H.; Weaver, D.; Chesebro, B.; Caughey, B. Structural aspects of Congo red as an inhibitor of protease-resistant prion protein formation. J. Neurochem., 1998, 71(6), 2534-2541.
68. Demaimay, R.; Chesebro, B.; Caughey, B. Inhibition of formation of protease-resistant prion protein by trypan blue, sirius red and other Congo red analogs. Arch. Virol. [Suppl], 2000, 16, 277-283.
69. Rudyk, H.; Vasiljevic, S.; Hennion, R.M.; Birkett, C.R.; Hope, J.; Gilbert, I.H. Screening Congo Red and its analogues for their ability to prevent the formation of PrP-res in scrapie-infected cells. J. Gen. Virol., 2000, 81, 1155-1164.
70. Poli, G.; Ponti, W.; Carcassola, G.; Ceciliani, F.; Colombo, L.; Dall'Ara, P.; Gervasoni, M.; Giannino, M.L.; Martino, P.A.; Pollera, C.; Villa, S.; Salmona, M. In vitro evaluation of the antiprionic activity of newly synthesized congo red derivatives. Arzneimittelforschung, 2003, 53(12), 875-888.
71. Kirby, L.; Birkett, C.R.; Rudyk, H.; Gilbert, I.H.; Hope, J. In vitro cell-free conversion of bacterial recombinant PrP to PrPres as a model for conversion. J. Gen. Virol., 2003, 84, 1013-1020.
72. Lucassen, R.; Nishina, K.; Supattapone, S. In vitro amplification of protease-resistant prion protein requires free sulfhydryl groups. Biochemistry (N. Y.), 2003, 42(14), 4127-4135.
73. Ingrosso, L.; Ladogana, A.; Pocchiari, M. Congo red prolongs the incubation period in scrapie-infected hamsters. J. Virol., 1995, 69, 506-508.
74. Poli, G.; Martino, P.A.; Villa, S.; Carcassola, G.; Giannino, M.L.; Dall'Ara, P.; Pollera, C.; Iussich, S.; Tranquillo, V.M.; Bareggi, S.; Mantegazza, P.; Ponti, W. Evaluation of anti-prion activity of congo red and its derivatives in experimentally infected hamsters. Arzneimittelforschung, 2004, 54(7), 406-415.
75. Gilch, S.; Winklhofer, K.F.; Groschup, M.H.; Nunziante, M.; Lucassen, R.; Spielhaupter, C.; Muranyi, W.; Riesner, D.; Tatzelt, J.; Schatzl, H.M. Intracellular re-routing of prion protein prevents propagation of PrP(Sc) and delays onset of prion disease. EMBO J., 2001, 20(15), 3957-3966.
76. Caughey, B.; Raymond, L.D.; Raymond, G.J.; Maxson, L.; Silveira, J.; Baron, G.S. Inhibition of protease-resistant prion protein accumulation in vitro by curcumin. J. Virol., 2003, 77(9), 5499-5502.
77. Hafner-Bratkovic, I.; Gaspersic, J.; Smid, L.M.; Bresjanac, M.; Jerala, R. Curcumin binds to the alpha-helical intermediate and to the amyloid form of prion protein-a new mechanism for the inhibition of PrP(Sc) accumulation. J. Neurochem., 2008, 104(6), 1553-1564.
78. Riemer, C.; Burwinkel, M.; Schwarz, A.; Gultner, S.; Mok, S.W.; Heise, I.; Holtkamp, N.; Baier, M. Evaluation of drugs for treatment of prion infections of the central nervous system. J. Gen. Virol., 2008, 89, 594-597.
79. Nunziante, M.; Kehler, C.; Maas, E.; Kassack, M.U.; Groschup, M.; Schatzl, H.M. Charged bipolar suramin derivatives induce aggregation of the prion protein at the cell surface and inhibit PrPSc replication. J. Cell. Sci., 2005, 118(, 4959-4973.
80. Hnasko, R.; Bruederle, C.E. Inoculation of scrapie with the selfassembling RADA-peptide disrupts prion accumulation and extends hamster survival. PLoS One, 2009, 4(2), e4440.
81. Berg, K.; Nordstrand, S.; Selbo, P.K.; Tran, D.T.; Angell-Petersen, E.; Hogset, A. Disulfonated tetraphenyl chlorin (TPCS2a), a novel photosensitizer developed for clinical utilization of photochemical internalization. Photochem. Photobiol. Sci., 2011, 10(10), 1637-1651.
82. Lee, K.S.; Raymond, L.D.; Schoen, B.; Raymond, G.J.; Kett, L.; Moore, R.A.; Johnson, L.M.; Taubner, L.; Speare, J.O.; Onwubiko, H.A.; Baron, G.S.; Caughey, W.S.; Caughey, B. Hemin interactions and alterations of the subcellular localization of prion protein. J. Biol. Chem., 2007, 282(50), 36525-36533.
83. Caughey, W.S.; Raymond, L.D.; Horiuchi, M.; Caughey, B. Inhibition of protease-resistant prion protein formation by porphyrins and phthalocyanines. Proc. Natl. Acad. Sci. USA, 1998, 95(21), 12117-12122.
84. Kocisko, D.A.; Caughey, W.S.; Race, R.E.; Roper, G.; Caughey, B.; Morrey, J.D. A porphyrin increases survival time of mice after intracerebral prion infection. Antimicrob. Agents Chemother., 2006, 50(2), 759-761.
85. Priola, S.A.; Raines, A.; Caughey, W.S. Porphyrin and phthalocyanine antiscrapie compounds. Science, 2000, 287(5457), 1503-1506.
86. Priola, S.A.; Raines, A.; Caughey, W. Prophylactic and therapeutic effects of phthalocyanine tetrasulfonate in scrapie-infected mice. J. Infect. Dis., 2003, 188(5), 699-705.
87. Abdel-Haq, H.; Lu, M.; Cardone, F.; Liu, Q.G.; Puopolo, M.; Pocchiari, M. Efficacy of phthalocyanine tetrasulfonate against mouseadapted human prion strains. Arch. Virol., 2009, 154(6), 1005-1007.
88. Kocisko, D.A.; Caughey, B.; Morrey, J.D.; Race, R.E. Enhanced antiscrapie effect using combination drug treatment. Antimicrob. Agents Chemother., 2006, 50(10), 3447-3449.
89. Forloni, G.; Iussich, S.; Awan, T.; Colombo, L.; Angeretti, N.; Girola, L.; Bertani, I.; Poli, G.; Caramelli, M.; Grazia, B.M.; Farina, L.; Limido, L.; Rossi, G.; Giaccone, G.; Ironside, J.W.; Bugiani, O.; Salmona, M.; Tagliavini, F. Tetracyclines affect prion infectivity. Proc. Natl. Acad. Sci. USA, 2002, 99(16), 10849-10854.
90. Guo, Y.J.; Han, J.; Yao, H.L.; Zhang, B.Y.; Gao, J.M.; Zhang, J.; Xiao, X.L.; Wang, X.F.; Zhao, W.Q.; Wang, D.X.; Dong, X.P. Treatment of scrapie pathogen 263K with tetracycline partially abolishes protease-resistant activity in vitro and reduces infectivity in vivo. Biomed. Environ. Sci., 2007, 20(3), 198-202.
91. Tagliavini, F.; Forloni, G.; Colombo, L.; Rossi, G.; Girola, L.; Canciani, B.; Angeretti, N.; Giampaolo, L.; Peressini, E.; Awan, T.; De, G.L.; Ragg, E.; Bugiani, O.; Salmona, M. Tetracycline affects abnormal properties of synthetic PrP peptides and PrP(Sc) in vitro. J. Mol. Biol., 2000, 300(5), 1309-1322.
92. Corato, M.; Ogliari, P.; Ceciliani, F.; Cova, E.; Bellotti, V.; Cereda, C.; Merlini, G.; Ceroni, M. Doxorubicin and congo red effectiveness on prion infectivity in golden Syrian hamster. Anticancer Res., 2009, 29(7), 2507-2512.
93. Doh-Ura, K.; Iwaki, T.; Caughey, B. Lysosomotropic agents and cysteine protease inhibitors inhibit scrapie-associated prion protein accumulation. J. Virol., 2000, 74(10), 4894-4897.
94. Korth, C.; May, B.C.; Cohen, F.E.; Prusiner, S.B. Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc. Natl. Acad. Sci. USA, 2001, 98(17), 9836-9841.
95. Ryou, C.; Legname, G.; Peretz, D.; Craig, J.C.; Baldwin, M.A.; Prusiner, S.B. Differential inhibition of prion propagation by enantiomers of quinacrine. Lab. Invest., 2003, 83(6), 837-843.
96. Kocisko, D.A.; Caughey, B. Mefloquine, an antimalaria drug with antiprion activity in vitro, lacks activity in vivo. J. Virol., 2006, 80(2), 1044-1046.
97. Collins, S.J.; Lewis, V.; Brazier, M.; Hill, A.F.; Fletcher, A.; Masters, C.L. Quinacrine does not prolong survival in a murine Creutzfeldt-Jakob disease model. Ann. Neurol., 2002, 52(4), 503-506.
98. Barret, A.; Tagliavini, F.; Forloni, G.; Bate, C.; Salmona, M.; Colombo, L.; De Luigi, A.; Limido, L.; Suardi, S.; Rossi, G.; Auvre, F.; Adjou, K.T.; Sales, N.; Williams, A.; Lasmezas, C.; Deslys, J.P. Evaluation of quinacrine treatment for prion diseases. J. Virol., 2003, 77(15), 8462-8469.
99. Roikhel, V.M.; Fokina, G.I.; Pogodina, V.V. Influence of aminasine on experimental scrapie in mice. Acta Virol., 1984, 28(4), 321-324.
100. Collinge, J.; Gorham, M.; Hudson, F.; Kennedy, A.; Keogh, G.; Pal, S.; Rossor, M.; Rudge, P.; Siddique, D.; Spyer, M.; Thomas, D.; Walker, S.; Webb, T.; Wroe, S.; Darbyshire, J. Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial. Lancet Neurol., 2009, 8(4), 334-344.
101. Mead, S.; Ranopa, M.; Gopalakrishnan, G.S.; Thompson, A.G.; Rudge, P.; Wroe, S.; Kennedy, A.; Hudson, F.; MacKay, A.; Darbyshire, J.H.; Collinge, J.; Walker, A.S. PRION-1 scales analysis supports use of functional outcome measures in prion disease. Neurology, 2011, 77(18), 1674-1683.
102. Ghaemmaghami, S.; Ahn, M.; Lessard, P.; Giles, K.; Legname, G.; DeArmond, S.J.; Prusiner, S.B. Continuous quinacrine treatment results in the formation of drug-resistant prions. PLoS Pathog., 2009, 5(11), e1000673.
103. Klingenstein, R.; Lober, S.; Kujala, P.; Godsave, S.; Leliveld, S.R.; Gmeiner, P.; Peters, P.J.; Korth, C. Tricyclic antidepressants, quinacrine and a novel, synthetic chimera thereof clear prions by destabilizing detergent-resistant membrane compartments. J. Neurochem., 2006, 98(3), 748-759.
104. Kishida, H.; Sakasegawa, Y.; Watanabe, K.; Yamakawa, Y.; Nishijima, M.; Kuroiwa, Y.; Hachiya, N.S.; Kaneko, K. Nonglycosylphosphatidylinositol (GPI)-anchored recombinant prion protein with dominant-negative mutation inhibits PrPSc replication in vitro. Amyloid, 2004, 11(1), 14-20.
105. Murakami-Kubo, I.; Doh-ura, K.; Ishikawa, K.; Kawatake, S.; Sasaki, K.; Kira, J.; Ohta, S.; Iwaki, T. Quinoline derivatives are therapeutic candidates for transmissible spongiform encephalopathies. J. Virol., 2004, 78(3), 1281-1288.
106. Chung, E.; Prelli, F.; Dealler, S.; Lee, W.S.; Chang, Y.T.; Wisniewski, T. Styryl-based and tricyclic compounds as potential antiprion agents. PLoS One, 2011, 6(9), e24844.
107. Thompson, M.J.; Borsenberger, V.; Louth, J.C.; Judd, K.E.; Chen, B. Design, synthesis, and structure-activity relationship of indole-3-glyoxylamide libraries possessing highly potent activity in a cell line model of prion disease. J. Med. Chem., 2009, 52(23), 7503-7511.
108. Thompson, M.J.; Louth, J.C.; Ferrara, S.; Sorrell, F.J.; Irving, B.J.; Cochrane, E.J.; Meijer, A.J.; Chen, B. Structure-activity relationship refinement and further assessment of indole-3-glyoxylamides as a lead series against prion disease. ChemMedChem, 2011, 6(1), 115-130.
109. Thompson, M.J.; Louth, J.C.; Ferrara, S.; Jackson, M.P.; Sorrell, F.J.; Cochrane, E.J.; Gever, J.; Baxendale, S.; Silber, B.M.; Roehl, H.H.; Chen, B. Discovery of 6-substituted indole-3-glyoxylamides as lead antiprion agents with enhanced cell line activity, improved microsomal stability and low toxicity. Eur. J. Med. Chem., 2011, 46(9), 4125-4132.
110. Rosenson, R.S.; Hislop, C.; McConnell, D.; Elliott, M.; Stasiv, Y.; Wang, N.; Waters, D.D.; PLASMA Investigators Effects of 1-Hindole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial. Lancet, 2009, 373(9664), 649-658.
111. Nicholls, S.J.; Cavender, M.A.; Kastelein, J.J.; Schwartz, G.; Waters, D.D.; Rosenson, R.S.; Bash, D.; Hislop, C. Inhibition of secretory phospholipase A(2) in patients with acute coronary syndromes: rationale and design of the vascular inflammation suppression to treat acute coronary syndrome for 16 weeks (VISTA-16) trial. Cardiovasc. Drugs Ther., 2012, 26(1), 71-75.
112. Wang, T.; Yin, Z.; Zhang, Z.; Bender, J.A.; Yang, Z.; Johnson, G.; Yang, Z.; Zadjura, L.M.; D'Arienzo, C.J.; DiGiugno Parker, D.; Gesenberg, C.; Yamanaka, G.A.; Gong, Y.F.; Ho, H.T.; Fang, H.; Zhou, N.; McAuliffe, B.V.; Eggers, B.J.; Fan, L.; Nowicka-Sans, B.; Dicker, I.B.; Gao, Q.; Colonno, R.J.; Lin, P.F.; Meanwell, N.A.; Kadow, J.F. Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-488043), a drug candidate that demonstrates antiviral activity in HIV-1-infected subjects. J. Med. Chem., 2009, 52(23), 7778-7787.
113. Oostendorp, R.L.; Witteveen, P.O.; Schwartz, B.; Vainchtein, L.D.; Schot, M.; Nol, A.; Rosing, H.; Beijnen, J.H.; Voest, E.E.; Schellens, J.H. Dose-finding and pharmacokinetic study of orally administered indibulin (D-24851) to patients with advanced solid tumors. Invest. New Drugs, 2010, 28(2), 163-170.
114. Ghaemmaghami, S.; May, B.C.; Renslo, A.R.; Prusiner, S.B. Discovery of 2-aminothiazoles as potent antiprion compounds. J. Virol., 2010, 84(7), 3408-3412.
115. Thompson, M.J.; Louth, J.C.; Greenwood, G.K.; Sorrell, F.J.; Knight, S.G.; Adams, N.B.; Chen, B. Improved 2,4-diarylthiazolebased antiprion agents: switching the sense of the amide group at C5 leads to an increase in potency. ChemMedChem, 2010, 5(9), 1476-1488.
116. Gallardo-Godoy, A.; Gever, J.; Fife, K.L.; Silber, B.M.; Prusiner, S.B.; Renslo, A.R. 2-Aminothiazoles as therapeutic leads for prion diseases. J. Med. Chem., 2011, 54(4), 1010-1021.
117. Chabry, J.; Caughey, B.; Chesebro, B. Specific inhibition of in vitro formation of protease-resistant prion protein by synthetic peptides. J. Biol. Chem., 1998, 273, 13203-13207.
118. Chabry, J.; Priola, S.A.; Wehrly, K.; Nishio, J.; Hope, J.; Chesebro, B. Species-independent inhibition of abnormal prion protein (PrP) formation by a peptide containing a conserved PrP sequence. J. Virol., 1999, 73(8), 6245-6250.
119. Horiuchi, M.; Baron, G.S.; Xiong, L.W.; Caughey, B. Inhibition of interactions and interconversions of prion protein isoforms by peptide fragments from the C-terminal folded domain. J. Biol. Chem., 2001, 276(18), 15489-15497.
120. Gilch, S.; Kehler, C.; Schatzl, H.M. Peptide aptamers expressed in the secretory pathway interfere with cellular PrPSc formation. J. Mol. Biol., 2007, 371(2), 362-373.
121. Soto, C.; Kascsak, R.J.; Saborio, G.P.; Aucouturier, P.; Wisniewski, T.; Prelli, F.; Kascsak, R.; Mendez, E.; Harris, D.A.; Ironside, J.; Tagliavini, F.; Carp, R.I.; Frangione, B. Reversion of prion protein conformational changes by synthetic beta-sheet breaker peptides. Lancet, 2000, 355(9199), 192-197.
122. Oishi, T.; Hagiwara, K.; Kinumi, T.; Yamakawa, Y.; Nishijima, M.; Nakamura, K.; Arimoto, H. Effects of beta-sheet breaker peptide polymers on scrapie-infected mouse neuroblastoma cells and their affinities to prion protein fragment PrP(81-145). Org. Biomol. Chem., 2003, 1(15), 2626-2629.
123. Hatcher, K.; Zheng, J.; Chen, S.G. Cryptic peptides of the kringle domains preferentially bind to disease-associated prion protein. J. Alzheimers Dis., 2009, 16(2), 421-431.
124. Westergard, L.; Turnbaugh, J.A.; Harris, D.A. A naturally occurring C-terminal fragment of the prion protein (PrP) delays disease and acts as a dominant-negative inhibitor of PrPSc formation. J. Biol. Chem., 2011, 286(51), 44234-44242.
125. Enari, M.; Flechsig, E.; Weissmann, C. Scrapie prion protein accumulation by scrapie-infected neuroblastoma cells abrogated by exposure to a prion protein antibody. Proc. Natl. Acad. Sci. USA, 2001, 98(16), 9295-9299.
126. Yuan, J.; Kinter, M.; McGeehan, J.; Perry, G.; Kneale, G.; Gambetti, P.; Zou, W.Q. Concealment of epitope by reduction and alkylation in prion protein. Biochem. Biophys. Res. Commun., 2005, 326(3), 652-659.
127. Zhou, X.; Bi, H.; Wong, J.; Shimoji, M.; Wang, Y.; Yuan, J.; Xiao, X.; Wang, G.X.; Zou, W.Q. Alkylating antitumor drug mechlorethamine conceals a structured PrP domain and inhibits in vitro prion amplification. J. Toxicol. Environ. Health A, 2011, 74(22-24), 1493-1503.
128. Gilch, S.; Kehler, C.; Schatzl, H.M. The prion protein requires cholesterol for cell surface localization. Mol. Cell. Neurosci., 2006, 31(2), 346-353.
129. Taraboulos, A.; Scott, M.; Semenov, A.; Avraham, D.; Laszlo, L.; Prusiner, S.B. Cholesterol depletion and modification of COOHterminal targeting sequence of the prion protein inhibit formation of the scrapie isoform. J. Cell Biol., 1995, 129, 121-132.
130. Bate, C.; Salmona, M.; Diomede, L.; Williams, A. Squalestatin cures prion-infected neurones and protects against prion neurotoxicity. J. Biol. Chem., 2004, 279(15), 14983-14990.
131. Pani, A.; Norfo, C.; Abete, C.; Mulas, C.; Putzolu, M.; Laconi, S.; Orru, C.D.; Cannas, M.D.; Vascellari, S.; La, C.P.; Dessi, S. Antiprion activity of cholesterol esterification modulators: a comparative study using ex vivo sheep fibroblasts and lymphocytes and mouse neuroblastoma cell lines. Antimicrob. Agents Chemother., 2007, 51(11), 4141-4147.
132. Hagiwara, K.; Nakamura, Y.; Nishijima, M.; Yamakawa, Y. Prevention of prion propagation by dehydrocholesterol reductase inhibitors in cultured cells and a therapeutic trial in mice. Biol. Pharm. Bull., 2007, 30(4), 835-838.
133. Kempster, S.; Bate, C.; Williams, A. Simvastatin treatment prolongs the survival of scrapie-infected mice. Neuroreport, 2007, 18(5), 479-482.
134. Mok, S.W.; Thelen, K.M.; Riemer, C.; Bamme, T.; Gultner, S.; Lutjohann, D.; Baier, M. Simvastatin prolongs survival times in prion infections of the central nervous system. Biochem. Biophys. Res. Commun., 2006, 348(2), 697-702.
135. Gilch, S.; Bach, C.; Lutzny, G.; Vorberg, I.; Schatzl, H.M. Inhibition of cholesterol recycling impairs cellular PrP(Sc) propagation. Cell Mol. Life Sci., 2009, 66(24), 3979-3991.
136. Demaimay, R.; Adjou, K.; Lasmezas, C.; Lazarini, F.; Cherifi, K.; Seman, M.; Deslys, J.P.; Dormont, D. Pharmacological studies of a new derivative of amphotericin B, MS-8209, in mouse and hamster scrapie. J. Gen. Virol., 1994, 75, 2499-2503.
137. Demaimay, R.; Adjou, K.T.; Beringue, V.; Demart, S.; Lasmezas, C.I.; Deslys, J.-.; Seman, M.; Dormont, D. Late treatment with polyene antibiotics can prolong the survival time of scrapieinfected animals. J. Virol., 1997, 71, 9685-9689.
138. Marella, M.; Lehmann, S.; Grassi, J.; Chabry, J. Filipin prevents pathological prion protein accumulation by reducing endocytosis and inducing cellular PrP release. J. Biol. Chem., 2002, 277(28), 25457-25464.
139. Adjou, K.T.; Demaimay, R.; Lasmezas, C.I.; Seman, M.; Deslys, J.P.; Dormont, D. Differential effects of a new amphotericin B derivative, MS-8209, on mouse BSE and scrapie: implications for the mechanism of action of polyene antibiotics. Res. Virol., 1996, 147(4), 213-218.
140. Masullo, C.; Macchi, G.; Xi, Y.G.; Pocchiari, M. Failure to ameliorate Creutzfeldt-Jakob disease with amphotericin B therapy. J. Infect. Dis., 1992, 165(4), 784-785.
141. Brandner, S.; Isenmann, S.; Raeber, A.; Fischer, M.; Sailer, A.; Kobayashi, Y.; Marino, S.; Weissmann, C.; Aguzzi, A. Normal host prion protein necessary for scrapie-induced neurotoxicity. Nature, 1996, 379(6563), 339-343.
142. Mallucci, G.R.; Ratte, S.; Asante, E.A.; Linehan, J.; Gowland, I.; Jefferys, J.G.; Collinge, J. Post-natal knockout of prion protein alters hippocampal CA1 properties, but does not result in neurodegeneration. EMBO J., 2002, 21(3), 202-210.
143. Mallucci, G.; Dickinson, A.; Linehan, J.; Klohn, P.C.; Brandner, S.; Collinge, J. Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis. Science, 2003, 302(5646), 871-874.
144. Mallucci, G.R.; White, M.D.; Farmer, M.; Dickinson, A.; Khatun, H.; Powell, A.D.; Brandner, S.; Jefferys, J.G.; Collinge, J. Targeting cellular prion protein reverses early cognitive deficits and neurophysiological dysfunction in prion-infected mice. Neuron, 2007, 53(3), 325-335.
145. Tilly, G.; Chapuis, J.; Vilette, D.; Laude, H.; Vilotte, J.L. Efficient and specific down-regulation of prion protein expression by RNAi. Biochem. Biophys. Res. Commun., 2003, 305(3), 548-551.
146. Daude, N.; Marella, M.; Chabry, J. Specific inhibition of pathological prion protein accumulation by small interfering RNAs. J. Cell. Sci., 2003, 116, 2775-2779.
147. Pfeifer, A.; Eigenbrod, S.; Al-Khadra, S.; Hofmann, A.; Mitteregger, G.; Moser, M.; Bertsch, U.; Kretzschmar, H. Lentivectormediated RNAi efficiently suppresses prion protein and prolongs survival of scrapie-infected mice. J. Clin. Invest., 2006, 116(12), 3204-3210.
148. You, H.; Tsutsui, S.; Hameed, S.; Kannanayakal, T.J.; Chen, L.; Xia, P.; Engbers, J.D.; Lipton, S.A.; Stys, P.K.; Zamponi, G.W. Abeta neurotoxicity depends on interactions between copper ions, prion protein, and N-methyl-D-aspartate receptors. Proc. Natl. Acad. Sci. USA, 2012, 109(5), 1737-1742.
149. Hijazi, N.; Shaked, Y.; Rosenmann, H.; Ben-Hur, T.; Gabizon, R. Copper binding to PrPC may inhibit prion disease propagation. Brain Res., 2003, 993(1-2), 192-200.
150. Sigurdsson, E.M.; Brown, D.R.; Alim, M.A.; Scholtzova, H.; Carp, R.; Meeker, H.C.; Prelli, F.; Frangione, B.; Wisniewski, T. Copper chelation delays the onset of prion disease. J. Biol. Chem., 2003, 278(47), 46199-46202.
151. Pollera, C.; Lucchini, B.; Formentin, E.; Bareggi, S.; Poli, G.; Ponti, W. Evaluation of anti-prionic activity of clioquinol in an in vivo model (Mesocricetus auratus). Vet. Res. Commun., 2005, 29(Suppl 2), 253-255.
152. Doh-ura, K.; Tamura, K.; Karube, Y.; Naito, M.; Tsuruo, T.; Kataoka, Y. Chelating compound, chrysoidine, is more effective in both antiprion activity and brain endothelial permeability than quinacrine. Cell. Mol. Neurobiol., 2007, 27(3), 303-316.
153. Fukuuchi, T.; Doh-ura, K.; Yoshihara, S.; Ohta, S. Metal complexes with superoxide dismutase-like activity as candidates for anti-prion drug. Bioorg. Med. Chem. Lett., 2006, 16(23), 5982-5987.
154. Bareggi, S.R.; Braida, D.; Pollera, C.; Bondiolotti, G.; Formentin, E.; Puricelli, M.; Poli, G.; Ponti, W.; Sala, M. Effects of clioquinol on memory impairment and the neurochemical modifications induced by scrapie infection in golden hamsters. Brain Res., 2009, 1280, 195-200.
155. Brazier, M.W.; Volitakis, I.; Kvasnicka, M.; White, A.R.; Underwood, J.R.; Green, J.E.; Han, S.; Hill, A.F.; Masters, C.L.; Collins, S.J. Manganese chelation therapy extends survival in a mouse model of M1000 prion disease. J. Neurochem., 2010, 114(2), 440-451.
156. Furlow, T.W., Jr.; Whitley, R.J.; Wilmes, F.J. Repeated suppression of Creutzfeldt-Jakob disease with vidarabine. Lancet, 1982, 2(8297), 564-565.
157. Pocchiari, M.; Casaccia, P.; Ladogana, A. Amphotericin B: a novel class of antiscrapie drugs. J. Infect. Dis., 1989, 160(5), 795-802.
158. Haig, D.A.; Clarke, M.C. The effect of beta-propiolactone on the scrapie agent. J. Gen. Virol., 1968, 3, 281-283.
159. Cochran, K.W. Failure of adenine arabinoside to modify scrapie in mice. J. Gen. Virol., 1971, 13(2), 353-354.
160. Kimberlin, R.H.; Walker, C.A. Antiviral compound effective against experimental scrapie. Lancet, 1979, 2(8142), 591-592.
161. Tateishi, J. Antibiotics and antivirals do not modify experimentally-induced Creutzfeldt-Jakob disease in mice. J. Neurol. Neurosurg. Psychiatry, 1981, 44(8), 723-724.
162. Hamanaka, T.; Sakasegawa, Y.; Ohmoto, A.; Kimura, T.; Ando, T.; Doh-ura, K. Anti-prion activity of protein-bound polysaccharide K in prion-infected cells and animals. Biochem. Biophys. Res. Commun., 2011, 405(2), 285-290.
163. Rieger, R.; Edenhofer, F.; Lasmezas, C.I.; Weiss, S. The human 37-kDa laminin receptor precursor interacts with the prion protein in eukaryotic cells. Nat. Med., 1997, 3(12), 1383-1388.
164. Hundt, C.; Peyrin, J.M.; Haik, S.; Gauczynski, S.; Leucht, C.; Rieger, R.; Riley, M.L.; Deslys, J.P.; Dormont, D.; Lasmezas, C.I.; Weiss, S. Identification of interaction domains of the prion protein with its 37-kDa/67-kDa laminin receptor. EMBO J., 2001, 20(21), 5876-5886.
165. Leucht, C.; Simoneau, S.; Rey, C.; Vana, K.; Rieger, R.; Lasmezas, C.I.; Weiss, S. The 37 kDa/67 kDa laminin receptor is required for PrP(Sc) propagation in scrapie-infected neuronal cells. EMBO Rep., 2003, 4(3), 290-295.
166. Gauczynski, S.; Nikles, D.; El-Gogo, S.; Papy-Garcia, D.; Rey, C.; Alban, S.; Barritault, D.; Lasmezas, C.I.; Weiss, S. The 37-kDa/67-kDa laminin receptor acts as a receptor for infectious prions and is inhibited by polysulfated glycanes. J. Infect. Dis., 2006, 194(5), 702-709.
167. Zuber, C.; Ludewigs, H.; Weiss, S. Therapeutic approaches targeting the prion receptor LRP/LR. Vet. Microbiol., 2007, 123(4), 387-393.
168. Zuber, C.; Knackmuss, S.; Rey, C.; Reusch, U.; Rottgen, P.; Frohlich, T.; Arnold, G.J.; Pace, C.; Mitteregger, G.; Kretzschmar, H.A.; Little, M.; Weiss, S. Single chain Fv antibodies directed against the 37 kDa/67 kDa laminin receptor as therapeutic tools in prion diseases. Mol. Immunol., 2008, 45(1), 144-151.
169. Yun, J.; Jin, H.T.; Lee, Y.J.; Choi, E.K.; Carp, R.I.; Jeong, B.H.; Kim, Y.S. The first report of RPSA polymorphisms, also called 37/67 kDa LRP/LR gene, in sporadic Creutzfeldt-Jakob disease (CJD). BMC Med. Genet., 2011, 12, 108.
170. Nordstrom, E.K.; Luhr, K.M.; Ibanez, C.; Kristensson, K. Inhibitors of the mitogen-activated protein kinase kinase 1/2 signaling pathway clear prion-infected cells from PrPSc. J. Neurosci., 2005, 25(37), 8451-8456.
171. Bate, C.; Reid, S.; Williams, A. Phospholipase A2 inhibitors or platelet-activating factor antagonists prevent prion replication. J. Biol. Chem., 2004, 279(35), 36405-36411.
172. Engelstein, R.; Grigoriadis, N.; Greig, N.H.; Ovadia, H.; Gabizon, R. Inhibition of P53-related apoptosis had no effect on PrP(Sc) accumulation and prion disease incubation time. Neurobiol. Dis., 2005, 18(2), 282-285.
173. Ertmer, A.; Gilch, S.; Yun, S.W.; Flechsig, E.; Klebl, B.; Stein-Gerlach, M.; Klein, M.A.; Schatzl, H.M. The tyrosine kinase inhibitor STI571 induces cellular clearance of PrPSc in prioninfected cells. J. Biol. Chem., 2004, 279(40), 41918-41927.
174. Yun, S.W.; Ertmer, A.; Flechsig, E.; Gilch, S.; Riederer, P.; Gerlach, M.; Schatzl, H.M.; Klein, M.A. The tyrosine kinase inhibitor imatinib mesylate delays prion neuroinvasion by inhibiting prion propagation in the periphery. J. Neurovirol., 2007, 13(4), 328-337.
175. Mays, C.E.; Ryou, C. Plasminogen stimulates propagation of protease-resistant prion protein in vitro. FASEB J., 2010, 24(12), 5102-5112.
176. Mays, C.E.; Ryou, C. Plasminogen: A cellular protein cofactor for PrPSc propagation. Prion, 2011, 5(1), 22-27.
177. Fischer, M.B.; Roeckl, C.; Parizek, P.; Schwarz, H.P.; Aguzzi, A. Binding of disease-associated prion protein to plasminogen. Nature, 2000, 408(6811), 479-483.
178. Ryou, C.; Prusiner, S.B.; Legname, G. Cooperative binding of dominant-negative prion protein to kringle domains. J. Mol. Biol., 2003, 329(2), 323-333.
179. Ryou, C.; Titlow, W.B.; Mays, C.E.; Bae, Y.; Kim, S. The suppression of prion propagation using poly-L-lysine by targeting plasminogen that stimulates prion protein conversion. Biomaterials, 2011, 32(11), 3141-3149.
180. Ayrolles-Torro, A.; Imberdis, T.; Torrent, J.; Toupet, K.; Baskakov, I.V.; Poncet-Montange, G.; Gregoire, C.; Roquet-Baneres, F.; Lehmann, S.; Rognan, D.; Pugniere, M.; Verdier, J.M.; Perrier, V. Oligomeric-induced activity by thienyl pyrimidine compounds traps prion infectivity. J. Neurosci., 2011, 31(42), 14882-14892.
181. Aguib, Y.; Heiseke, A.; Gilch, S.; Riemer, C.; Baier, M.; Schatzl, H.M.; Ertmer, A. Autophagy induction by trehalose counteracts cellular prion infection. Autophagy, 2009, 5(3), 361-369.
182. Supattapone, S.; Nguyen, H.O.; Cohen, F.E.; Prusiner, S.B.; Scott, M.R. Elimination of prions by branched polyamines and implications for therapeutics. Proc. Natl. Acad. Sci. USA, 1999, 96(25), 14529-14534.
183. Supattapone, S.; Wille, H.; Uyechi, L.; Safar, J.; Tremblay, P.; Szoka, F.C.; Cohen, F.E.; Prusiner, S.B.; Scott, M.R. Branched polyamines cure prion-infected neuroblastoma cells. J. Virol., 2001, 75(7), 3453-3461.
184. Solassol, J.; Crozet, C.; Perrier, V.; Leclaire, J.; Beranger, F.; Caminade, A.M.; Meunier, B.; Dormont, D.; Majoral, J.P.; Lehmann, S. Cationic phosphorus-containing dendrimers reduce prion replication both in cell culture and in mice infected with scrapie. J. Gen. Virol., 2004, 85, 1791-1799.
185. Bera, A.; Nandi, P.K. Biological polyamines inhibit nucleic-acidinduced polymerisation of prion protein. Arch. Virol., 2007, 152(4), 655-668.
186. Winklhofer, K.F.; Tatzelt, J. Cationic lipopolyamines induce degradation of PrPSc in scrapie-infected mouse neuroblastoma cells. Biol. Chem., 2000, 381(5-6), 463-469.
187. Lim, Y.B.; Mays, C.E.; Kim, Y.; Titlow, W.B.; Ryou, C. The inhibition of prions through blocking prion conversion by permanently charged branched polyamines of low cytotoxicity. Biomaterials, 2010, 31(8), 2025-2033.
188. Chai, Y.; Koppenhafer, S.L.; Bonini, N.M.; Paulson, H.L. Analysis of the role of heat shock protein (Hsp) molecular chaperones in polyglutamine disease. J. Neurosci., 1999, 19(23), 10338-10347.
189. Warrick, J.M.; Chan, H.Y.; Gray-Board, G.L.; Chai, Y.; Paulson, H.L.; Bonini, N.M. Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70. Nat. Genet., 1999, 23(4), 425-428.
190. Bailey, C.K.; Andriola, I.F.; Kampinga, H.H.; Merry, D.E. Molecular chaperones enhance the degradation of expanded polyglutamine repeat androgen receptor in a cellular model of spinal and bulbar muscular atrophy. Hum. Mol. Genet., 2002, 11(5), 515-523.
191. Fujimoto, M.; Takaki, E.; Hayashi, T.; Kitaura, Y.; Tanaka, Y.; Inouye, S.; Nakai, A. Active HSF1 significantly suppresses polyglutamine aggregate formation in cellular and mouse models. J. Biol. Chem., 2005, 280(41), 34908-34916.
192. Muchowski, P.J.; Schaffar, G.; Sittler, A.; Wanker, E.E.; Hayer-Hartl, M.K.; Hartl, F.U. Hsp70 and hsp40 chaperones can inhibit self-assembly of polyglutamine proteins into amyloid-like fibrils. Proc. Natl. Acad. Sci. USA, 2000, 97(14), 7841-7846.
193. Wacker, J.L.; Zareie, M.H.; Fong, H.; Sarikaya, M.; Muchowski, P.J. Hsp70 and Hsp40 attenuate formation of spherical and annular polyglutamine oligomers by partitioning monomer. Nat. Struct. Mol. Biol., 2004, 11(12), 1215-1222.
194. Wyttenbach, A.; Carmichael, J.; Swartz, J.; Furlong, R.A.; Narain, Y.; Rankin, J.; Rubinsztein, D.C. Effects of heat shock, heat shock protein 40 (HDJ-2), and proteasome inhibition on protein aggregation in cellular models of Huntington's disease. Proc. Natl. Acad. Sci. USA, 2000, 97(6), 2898-2903.
195. Booth, S.; Bowman, C.; Baumgartner, R.; Dolenko, B.; Sorensen, G.; Robertson, C.; Coulthart, M.; Phillipson, C.; Somorjai, R. Molecular classification of scrapie strains in mice using gene expression profiling. Biochem. Biophys. Res. Commun., 2004, 325(4), 1339-1345.
196. Diedrich, J.F.; Carp, R.I.; Haase, A.T. Increased expression of heat shock protein, transferrin, and beta 2-microglobulin in astrocytes during scrapie. Microb. Pathog., 1993, 15(1), 1-6.
197. Kenward, N.; Hope, J.; Landon, M.; Mayer, R.J. Expression of polyubiquitin and heat-shock protein 70 genes increases in the later stages of disease progression in scrapie-infected mouse brain. J. Neurochem., 1994, 62(5), 1870-1877.
198. Sawiris, G.P.; Becker, K.G.; Elliott, E.J.; Moulden, R.; Rohwer, R.G. Molecular analysis of bovine spongiform encephalopathy infection by cDNA arrays. J. Gen. Virol., 2007, 88(Pt 4), 1356-1362.
199. Tatzelt, J.; Voellmy, R.; Welch, W.J. Abnormalities in stress proteins in prion diseases. Cell Mol. Neurobiol., 1998, 18(6), 721-729.
200. Serrano, C.; Bolea, R.; Lyahyai, J.; Filali, H.; Varona, L.; Marcos-Carcavilla, A.; Acin, C.; Calvo, J.H.; Serrano, M.; Badiola, J.J.; Zaragoza, P.; Martin-Burriel, I. Changes in HSP gene and protein expression in natural scrapie with brain damage. Vet. Res., 2011, 42(1), 13.
201. Neef, D.W.; Jaeger, A.M.; Thiele, D.J. Heat shock transcription factor 1 as a therapeutic target in neurodegenerative diseases. Nat. Rev. Drug Discov., 2011, 10(12), 930-944.
202. Relano-Gines, A.; Lehmann, S.; Bencsik, A.; Herva, M.E.; Torres, J.M.; Crozet, C.A. Stem cell therapy extends incubation and survival time in prion-infected mice in a time window-dependant manner. J. Infect. Dis., 2011, 204(7), 1038-1045.
203. Torres, M.; Encina, G.; Soto, C.; Hetz, C. Abnormal calcium homeostasis and protein folding stress at the ER: A common factor in familial and infectious prion disorders. Commun. Integr. Biol., 2011, 4(3), 258-261.
204. Mukherjee, A.; Morales-Scheihing, D.; Gonzalez-Romero, D.; Green, K.; Taglialatela, G.; Soto, C. Calcineurin inhibition at the clinical phase of prion disease reduces neurodegeneration, improves behavioral alterations and increases animal survival. PLoS Pathog., 2010, 6(10), e1001138.
205. Otto, M.; Cepek, L.; Ratzka, P.; Doehlinger, S.; Boekhoff, I.; Wiltfang, J.; Irle, E.; Pergande, G.; Ellers-Lenz, B.; Windl, O.; Kretzschmar, H.A.; Poser, S.; Prange, H. Efficacy of flupirtine on cognitive function in patients with CJD: A double-blind study. Neurology, 2004, 62(5), 714-718.
206. Muller, W.E.; Romero, F.J.; Perovic, S.; Pergande, G.; Pialoglou, P. Protection of flupirtine on beta-amyloid-induced apoptosis in neuronal cells in vitro: prevention of amyloid-induced glutathione depletion. J. Neurochem., 1997, 68(6), 2371-2377.
207. Perovic, S.; Schroder, H.C.; Pergande, G.; Ushijima, H.; Muller, W.E. Effect of flupirtine on Bcl-2 and glutathione level in neuronal cells treated in vitro with the prion protein fragment (PrP106-126). Exp. Neurol., 1997, 147(2), 518-524.
208. Dirikoc, S.; Priola, S.A.; Marella, M.; Zsurger, N.; Chabry, J. Nonpsychoactive cannabidiol prevents prion accumulation and protects neurons against prion toxicity. J. Neurosci., 2007, 27(36), 9537-9544.
209. Brown, D.R. Neurodegeneration and oxidative stress: prion disease results from loss of antioxidant defence. Folia Neuropathol., 2005, 43(4), 229-243.
210. Muyrers, J.; Klingenstein, R.; Stitz, L.; Korth, C. Structure-activity relationship of tocopherol derivatives suggesting a novel nonantioxidant mechanism in antiprion potency. Neurosci. Lett., 2010, 469(1), 122-126.
211. Crozet, C.; Lin, Y.L.; Mettling, C.; Mourton-Gilles, C.; Corbeau, P.; Lehmann, S.; Perrier, V. Inhibition of PrPSc formation by lentiviral gene transfer of PrP containing dominant negative mutations. J. Cell. Sci., 2004, 117, 5591-5597.
212. Singh, M.P.; Meyer zu Horste, G.; Hu, W.; Mausberg, A.K.; Cravens, P.D.; Eagar, T.; Lober, S.; Klingenstein, R.; Gmeiner, P.; Korth, C.; Kieseier, B.C.; Stuve, O. Quinpramine is a novel compound effective in ameliorating brain autoimmune disease. Exp. Neurol., 2009, 215(2), 397-400.
213. Meyer zu Horste, G.; Mausberg, A.K.; Muller, J.I.; Lehmann, H.C.; Lober, S.; Gmeiner, P.; Hartung, H.P.; Stuve, O.; Korth, C.; Kieseier, B.C. Quinpramine ameliorates rat experimental autoimmune neuritis and redistributes MHC class II molecules. PLoS One, 2011, 6(6), e21223.
214. Birkett, C.R.; Hennion, R.M.; Bembridge, D.A.; Clarke, M.C.; Chree, A.; Bruce, M.E.; Bostock, C.J. Scrapie strains maintain biological phenotypes on propagation in a cell line in culture. EMBO J., 2001, 20(13), 3351-3358.
215. Kimberlin, R.H.; Walker, C.A. Suppression of scrapie infection in mice by heteropolyanion 23, dextran sulfate, and some other polyanions. Antimicrob. Agents Chemother., 1986, 30, 409-413.
216. Adjou, K.T.; Simoneau, S.; Sales, N.; Lamoury, F.; Dormont, D.; Papy-Garcia, D.; Barritault, D.; Deslys, J.P.; Lasmezas, C.I. A novel generation of heparan sulfate mimetics for the treatment of prion diseases. J. Gen. Virol., 2003, 84, 2595-2603.
217. Schonberger, O.; Horonchik, L.; Gabizon, R.; Papy-Garcia, D.; Barritault, D.; Taraboulos, A. Novel heparan mimetics potently inhibit the scrapie prion protein and its endocytosis. Biochem. Biophys. Res. Commun., 2003, 312(2), 473-479.
218. Doh-ura, K.; Kuge, T.; Uomoto, M.; Nishizawa, K.; Kawasaki, Y.; Iha, M. Prophylactic effect of dietary seaweed Fucoidan against enteral prion infection. Antimicrob. Agents Chemother., 2007, 51(6), 2274-2277.
219. Kimberlin, R.H.; Walker, C.A. The antiviral compound HPA-23 can prevent scrapie when administered at the time of infection. Arch. Virol., 1983, 78, 9-18.
220. Proske, D.; Gilch, S.; Wopfner, F.; Schatzl, H.M.; Winnacker, E.L.; Famulok, M. Prion-protein-specific aptamer reduces PrPSc formation. Chembiochem., 2002, 3(8), 717-725.
221. Rhie, A.; Kirby, L.; Sayer, N.; Wellesley, R.; Disterer, P.; Sylvester, I.; Gill, A.; Hope, J.; James, W.; Tahiri-Alaoui, A. Characterization of 2'-fluoro-RNA aptamers that bind preferentially to disease-associated conformations of prion protein and inhibit conversion. J. Biol. Chem., 2003, 278(41), 39697-39705.
222. Engelstein, R.; Ovadia, H.; Gabizon, R. Copaxone interferes with the PrP Sc-GAG interaction. Eur. J. Neurol., 2007, 14(8), 877-884.
223. Haik, S.; Brandel, J.P.; Salomon, D.; Sazdovitch, V.; asnerie-Laupretre, N.; Laplanche, J.L.; Faucheux, B.A.; Soubrie, C.; Boher, E.; Belorgey, C.; Hauw, J.J.; Alperovitch, A. Compassionate use of quinacrine in Creutzfeldt-Jakob disease fails to show significant effects. Neurology, 2004, 63(12), 2413-2415.
224. Mange, A.; Nishida, N.; Milhavet, O.; McMahon, H.E.; Casanova, D.; Lehmann, S. Amphotericin B inhibits the generation of the scrapie isoform of the prion protein in infected cultures. J. Virol., 2000, 74(7), 3135-3140.
225. Pocchiari, M.; Schmittinger, S.; Masullo, C. Amphotericin B delays the incubation period of scrapie in intracerebrally inoculated hamsters. J. Gen. Virol., 1987, 68, 219-223.
226. Xi, Y.G.; Ingrosso, L.; Ladogana, A.; Masullo, C.; Pocchiari, M. Amphotericin B treatment dissociates in vivo replication of the scrapie agent from PrP accumulation. Nature, 1992, 356(6370), 598-601.
227. McKenzie, D.; Kaczkowski, J.; Marsh, R.; Aiken, J.M. Amphotericin B delays both scrapie agent replication and PrP-res accumulation early in infection. J. Virol., 1994, 68, 7534-7536.
228. Adjou, K.T.; Demaimay, R.; Lasmezas, C.; Deslys, J.-.; Seman, M.; Dormont, D. MS-8209, a new amphotericin B derivative, provides enhanced efficacy in delaying hamster scrapie. Antimicrob. Agents Chemother., 1995, 39, 2810-2812.
229. Adjou, K.T.; Demaimay, R.; Deslys, J.P.; Lasmezas, C.I.; Beringue, V.; Demart, S.; Lamoury, F.; Seman, M.; Dormont, D. MS-8209, a water-soluble amphotericin B derivative, affects both scrapie agent replication and PrPres accumulation in Syrian hamster scrapie. J. Gen. Virol., 1999, 80(Pt 4), 1079-1085.
230. Adjou, K.T.; Privat, N.; Demart, S.; Deslys, J.P.; Seman, M.; Hauw, J.J.; Dormont, D. MS-8209, an amphotericin B analogue, delays the appearance of spongiosis, astrogliosis and PrPres accumulation in the brain of scrapie-infected hamsters. J. Comp. Pathol., 2000, 122(1), 3-8.
231. Qin, K.; Yang, D.S.; Yang, Y.; Chishti, M.A.; Meng, L.J.; Kretzschmar, H.A.; Yip, C.M.; Fraser, P.E.; Westaway, D. Copper(II)-induced conformational changes and protease resistance in recombinant and cellular PrP. Effect of protein age and deamidation. J. Biol. Chem., 2000, 275(25), 19121-19131.
232. Thackray, A.M.; Yang, S.; Wong, E.; Fitzmaurice, T.J.; Morgan-Warren, R.J.; Bujdoso, R. Conformational variation between allelic variants of cell-surface ovine prion protein. Biochem. J., 2004, 381, 221-229.
233. Giese, A.; Levin, J.; Bertsch, U.; Kretzschmar, H. Effect of metal ions on de novo aggregation of full-length prion protein. Biochem. Biophys. Res. Commun., 2004, 320(4), 1240-1246.
234. Kuczius, T.; Buschmann, A.; Zhang, W.; Karch, H.; Becker, K.; Peters, G.; Groschup, M.H. Cellular prion protein acquires resistance to proteolytic degradation following copper ion binding. Biol. Chem., 2004, 385(8), 739-747.
235. Kim, N.H.; Choi, J.K.; Jeong, B.H.; Kim, J.I.; Kwon, M.S.; Carp, R.I.; Kim, Y.S. Effect of transition metals (Mn, Cu, Fe) and deoxycholic acid (DA) on the conversion of PrPC to PrPres. FASEB J., 2005, 19(7), 783-785.
236. Bocharova, O.V.; Breydo, L.; Salnikov, V.V.; Baskakov, I.V. Copper(II) inhibits in vitro conversion of prion protein into amyloid fibrils. Biochemistry (N. Y.), 2005, 44(18), 6776-6787.
237. Orem, N.R.; Geoghegan, J.C.; Deleault, N.R.; Kascsak, R.; Supattapone, S. Copper (II) ions potently inhibit purified PrPres amplification. J. Neurochem., 2006, 96(5), 1409-1415.
238. Treiber, C.; Simons, A.; Multhaup, G. Effect of copper and manganese on the de novo generation of protease-resistant prion protein in yeast cells. Biochemistry (N. Y.), 2006, 45(21), 6674-6680.
239. Sim, V.L.; Caughey, B. Recent advances in prion chemotherapeutics. Infect. Disord. Drug Targets, 2009, 9(1), 81-91.